Severe COVID patients continue to evidence lung abnormalities 2 years after initial infection

Two-year follow-up data from patients who had severe COVID reveals that some continue to display lung abnormalities two years after initially acquiring the virus [1]. 

These latest findings were published Feb. 14 in Radiology

The analysis includes chest CT scans from a cohort of 144 patients who had been hospitalized with COVID between January 15 and March 10, 2020. Each participant underwent a total of three chest CTs in order to be included in the analysis—one at six months, 12 months and two years following the onset of their symptoms.  

Those scans showed a combination of fibrosis, thickening, honeycombing, cystic changes and dilation of the bronchi, among other imaging features. 

Co-senior authors of the study Qing Ye, MD, and Heshui Shi, MD, PhD, both with Tongji Medical College of Huazhong University of Science and Technology in Wuhan, China, and colleagues noted that the finding of fibrosis is of particular concern. 

“In particular, the proportion of fibrotic interstitial lung abnormalities, an important precursor to idiopathic pulmonary fibrosis, remained stable throughout follow-up,” the authors said. “Therefore, the fibrotic abnormalities observed in our study might represent a stable, irreversible pulmonary condition, such as lung fibrosis, after COVID-19.” 

The good news is that many of the other lung abnormalities visualized at six months appeared to decrease over time. At six months, 54% of patients showed abnormalities, but by the two-year mark, that figure decreased to 39%, with 61% showing complete radiological resolution.

Of the patients who continued to show abnormalities on imaging, 23% were found to be fibrotic, and 22% still harbored respiratory symptoms and decreased lung function. For the symptomatic, the most common issue was noted as exertional dyspnea or shortness of breath. The authors suggested that these lingering symptoms could likely be attributed to their ongoing lung damage, but that the “long-term and functional consequences of chest CT findings post-COVID-19 are largely unknown.” 

The experts suggested that patients who continue to show respiratory symptoms following the recovery from their initial infection need to be continuously monitored for functional impairment. 

The study abstract is available here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.